Were Corcept Therapeutics (CORT) CFO’s share sales made under a Rule 10b5-1 plan?

Yes. A footnote explains the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2025. Such plans pre-schedule trades, which means the timing of these sales was set in advance rather than decided on the transaction date.

Corcept Therapeutics (CORT) CFO exercises options, sells 40,000 shares in 10b5-1 trades

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Corcept Therapeutics’ Chief Financial Officer Atabak Mokari reported option exercises and related share sales in the company’s common stock. He exercised stock options covering 40,000 shares at an exercise price of $19.26 per share, then sold 40,000 shares in multiple open-market transactions at weighted average prices between approximately $79.40 and $82.18 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly holds 16,130 common shares, which include shares underlying several unvested restricted stock awards scheduled to vest on their one-year anniversaries if service conditions are met.

Insider Trade Summary 10b5-1

Net Seller: 40,000 shares ($3,245,900)

Net Sell 6 txns

Insider Mokari Atabak

Role Chief Financial Officer

Sold 40,000 shs ($3.25M)

Type	Security	Shares	Price	Value
Exercise	Stock option (right to buy)	40,000	$0.00	--
Exercise	Common Stock	40,000	$19.26	$770K
Sale	Common Stock	9,434	$80.0216	$755K
Sale	Common Stock	11,081	$80.9424	$897K
Sale	Common Stock	19,483	$81.8092	$1.59M
Sale	Common Stock	2	$82.45	$164.90

Holdings After Transaction: Stock option (right to buy) — 20,000 shares (Direct, null); Common Stock — 56,130 shares (Direct, null)

Footnotes (1)

Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.40 to $80.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.40 to $81.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.40 to $82.18 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Fully exercisable.

Key Figures

Shares sold: 40,000 shares Option exercise shares: 40,000 shares Exercise price: $19.26 per share +5 more

8 metrics

Shares sold 40,000 shares Total common shares sold in open-market transactions on June 15, 2026

Option exercise shares 40,000 shares Common shares acquired via stock option exercise on June 15, 2026

Exercise price $19.26 per share Strike price of stock options exercised for 40,000 shares

Post-transaction holdings 16,130 shares Direct common stock owned by CFO after reported transactions

Highest weighted average sale price $82.45 per share Weighted average price for one sale tranche of 2 shares

Lowest price range bound $79.40 per share Lowest individual sale price in disclosed trade ranges

Highest price range bound $82.18 per share Highest individual sale price in disclosed trade ranges

Remaining options after exercise 20,000 options Stock options still held after exercising 40,000, as reported

Key Terms

Rule 10b5-1 plan, restricted stock awards, stock option (right to buy), derivative security, +1 more

5 terms

Rule 10b5-1 plan regulatory

"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person..."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

restricted stock awards financial

"Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person..."

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

stock option (right to buy) financial

"security_title: "Stock option (right to buy)" with underlying security title Common Stock"

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

weighted average sale price financial

"Represents the weighted average sale price for the entire number of shares sold."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/17/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mokari Atabak

(Last)

(First)

(Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY

CALIFORNIA

94065

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/15/2026		M		40,000	A	$19.26	56,130⁽¹⁾	D
Common Stock	06/15/2026		S⁽²⁾		9,434	D	$80.0216⁽³⁾	46,696⁽¹⁾	D
Common Stock	06/15/2026		S⁽²⁾		11,081	D	$80.9424⁽⁴⁾	35,615⁽¹⁾	D
Common Stock	06/15/2026		S⁽²⁾		19,483	D	$81.8092⁽⁵⁾	16,132⁽¹⁾	D
Common Stock	06/15/2026		S⁽²⁾		2	D	$82.45	16,130⁽¹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock option (right to buy)	$19.26	06/15/2026		M			40,000	⁽⁶⁾	02/02/2032	Common Stock	40,000	$0.00	20,000	D

Explanation of Responses:

1. Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.40 to $80.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.40 to $81.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.40 to $82.18 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

6. Fully exercisable.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Atabak Mokari	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Corcept Therapeutics (CORT) CFO Atabak Mokari report?

Corcept Therapeutics CFO Atabak Mokari reported exercising stock options for 40,000 common shares at $19.26 per share and selling 40,000 shares in multiple open-market transactions at weighted average prices between about $79.40 and $82.18, under a pre-arranged Rule 10b5-1 plan.

At what prices did Corcept Therapeutics (CORT) CFO sell shares in this Form 4?

The CFO’s reported open-market sales used weighted average prices around $80.02, $80.94, $81.81, and $82.45 per share. Footnotes state actual sale prices ranged from $79.40 to $82.18, with detailed trade breakdowns available from the company upon request.

How many Corcept Therapeutics (CORT) shares does the CFO hold after these transactions?

After the reported option exercise and related sales, the CFO directly owns 16,130 shares of Corcept Therapeutics common stock. This total also reflects shares underlying several unvested restricted stock awards that are scheduled to vest on their one-year grant anniversaries if specified conditions are satisfied.

What stock option activity did the Corcept Therapeutics (CORT) CFO report?

The Form 4 shows the CFO exercised stock options covering 40,000 shares of common stock at an exercise price of $19.26 per share. A related derivative entry notes these options are now fully exercisable and had an original expiration date in 2032 before exercise.